Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

This study is testing CAR T-cell therapy — where a patient's own immune cells are genetically reprogrammed to attack cancer cells expressing a protein called CD19 — in people with B-cell leukemia, lymphoma, or CLL that has relapsed or stopped responding to standard treatments. **You may be eligible if...** - You are between 2 and 70 years old - You have relapsed or refractory ALL (leukemia), B-cell lymphoma, or CLL that has been treated with at least two prior therapies - Your cancer tests positive for the CD19 protein - Your performance status meets criteria (ECOG ≤ 2 for adults; Lansky ≥ 50% for children under 16) - Your liver, kidney, and heart function are within acceptable limits **You may NOT be eligible if...** - Your cancer does not express CD19 - You have not received at least two prior lines of treatment - You have unacceptable organ dysfunction - You have active autoimmune disease or active serious infection Talk to your doctor to see if this trial is right for you.